OTCMKTS:BPMUF Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis $76.25 0.00 (0.00%) As of 10/2/2026 10:31 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsShort Interest About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Basilea Pharmaceutica alerts:Sign Up Key Stats Today's Range$76.25▼$76.2550-Day Range$60.28▼$77.4052-Week Range$59.29▼$77.40Volume10 shsAverage Volume1 shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Basilea Pharmaceutica Ltd. is a Switzerland-based biopharmaceutical company focused on developing and commercializing medicines for serious bacterial and fungal infections. The company’s portfolio is intended primarily for use in hospitals and other specialized-care settings where drug-resistant pathogens and complex infections present significant treatment challenges. Basilea’s key products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), a cephalosporin antibiotic used for certain serious bacterial infections. The company also conducts research and development in anti-infective therapies and works with commercial partners to expand the availability of its products. Founded in 2000 as a spin-off from Roche, Basilea is headquartered in Basel, Switzerland. Its medicines are marketed in multiple international regions through a combination of its own commercial activities and licensing or distribution partnerships. Basilea’s leadership includes Chief Executive Officer Marc Gitzinger, who has led the company since 2010.AI Generated. May Contain Errors. Read More Receive BPMUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPMUF Stock News HeadlinesBasilea Pharmaceutica AG (OTCMKTS:BPMUF) Stock Short Interest Rises 187.8%September 27, 2026 | americanbankingnews.comBasilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactamMay 28, 2026 | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meetingApril 15, 2026 | globenewswire.comBasilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420April 9, 2026 | globenewswire.comBasilea announces start of first‑in‑human study of novel antibiotic BAL2420March 23, 2026 | globenewswire.comBasilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactamFebruary 25, 2026 | globenewswire.comBasilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call TranscriptFebruary 17, 2026 | seekingalpha.comSee More Headlines BPMUF Stock Analysis - Frequently Asked Questions How have BPMUF shares performed this year? Basilea Pharmaceutica's stock was trading at $63.25 at the start of the year. Since then, BPMUF stock has increased by 20.6% and is now trading at $76.25. Does Basilea Pharmaceutica have any subsidiaries? Basilea Pharmaceutica subsidiaries include Conec UK Limited. How do I buy shares of Basilea Pharmaceutica? Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:BPMUF CIKN/A Webwww.basilea.com Phone(161) 606-1111Fax41-61-606-1112Employees189Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$280.43 million Price / Sales3.58 Cash Flow$3.85 per share Price / Cash Flow19.81 Book Value$11.73 per share Price / Book6.50Miscellaneous Outstanding Shares13,170,000Free FloatN/AMarket Cap$1.00 billion OptionableNot Optionable Beta0.22 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:BPMUF) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Basilea Pharmaceutica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPMUF Stock Alerts